Health Care • Misc Health and Biotechnology Services
$5.19 ▲ +0.06
(+1.17%)
MKT CAP: $41.8M • VOL: 8.1K
52W L $3 52W H $5
ROARABLE / RQD
C • 64/100
PIOTROSKI
3 / 9
CCEL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-11-30 | FY 2024
FILED 2024-11-30 | FY 2023
FILED 2023-11-30 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $482.4K | $3.5M | -$12.3M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$2.4M | $402.0K | -$9.5M |
| EBITDA (Normalized) | $666.8K | $5.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $5.5M | $6.0M | $8.9M |
| Capital Expenditures (CapEx) | $230.5K | $2.4M | — |
| Free Cash Flow (FCF) | $5.2M | $3.6M | $8.9M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | 95.0% | 95.0% | — |
| Cash & Short-Term Equivalents | $319.0K | $561.0K | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$18.6M | -$13.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CCEL.